Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Jagsonpal Pharmaceuticals Ltd

₹ 210 -1.18%
13 May - close price
jagsonpal.com BSE: 507789 NSE: JAGSNPHARM
About

Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]

Key Points

Business Overview:[1][2]
a) JPL provides essential medicines for women-specific healthcare needs, through Gynaecology and Orthopaedics as its focus segments.
b) It is also present in major therapeutic sub-segments viz. antibiotics, allergy management, immunity and cell protection, OTC products, dermatology and pediatrics segment
c) JPL has 17 brands amongst Top 5 brands in the molecule category. It has a pan-India presence through its strong sales team of 900+ individuals. In FY24, company generated ~47% of its revenues from its top 5 brands and ~67% from its top 7 brands

Website BSE NSE
  • Market Cap ₹ 1,406 Cr.
  • Current Price ₹ 210
  • High / Low ₹ 302 / 155
  • Stock P/E 31.5
  • Book Value ₹ 41.2
  • Dividend Yield 1.19 %
  • ROCE 22.7 %
  • ROE 17.3 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 50.3%
  • Company's working capital requirements have reduced from 24.0 days to 11.0 days

Cons

  • The company has delivered a poor sales growth of 8.85% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
55.45 60.15 57.83 47.23 43.49 61.44 74.69 74.03 58.56 75.61 74.47 72.95 64.20
50.01 51.52 49.46 43.83 40.82 51.19 58.40 58.19 49.85 61.41 58.03 56.68 53.04
Operating Profit 5.44 8.63 8.37 3.40 2.67 10.25 16.29 15.84 8.71 14.20 16.44 16.27 11.16
OPM % 9.81% 14.35% 14.47% 7.20% 6.14% 16.68% 21.81% 21.40% 14.87% 18.78% 22.08% 22.30% 17.38%
2.56 2.00 2.27 2.52 2.49 -1.85 1.65 25.51 2.56 2.83 3.03 0.90 3.17
Interest 0.20 0.15 0.22 0.23 0.22 0.22 0.23 0.26 0.26 0.25 0.27 0.26 0.25
Depreciation 0.48 0.39 0.46 0.41 0.40 1.07 2.34 2.41 2.31 2.35 2.39 2.39 2.32
Profit before tax 7.32 10.09 9.96 5.28 4.54 7.11 15.37 38.68 8.70 14.43 16.81 14.52 11.76
Tax % 23.50% 25.87% 25.00% 24.81% 21.59% 25.04% 25.44% 17.27% 24.48% 25.23% 25.22% 24.59% 25.43%
5.60 7.48 7.47 3.96 3.55 5.33 11.46 31.99 6.58 10.80 12.57 10.95 8.76
EPS in Rs 0.85 1.14 1.14 0.60 0.54 0.81 1.73 4.82 0.99 1.62 1.89 1.64 1.31
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
138 143 144 127 167 159 188 218 237 209 269 287
129 132 138 138 157 150 169 192 203 186 218 229
Operating Profit 9 12 6 -11 9 9 19 26 34 23 51 58
OPM % 6% 8% 4% -9% 6% 5% 10% 12% 14% 11% 19% 20%
0 1 13 0 1 3 4 3 2 9 28 10
Interest 4 5 3 1 1 1 1 0 0 1 1 1
Depreciation 3 3 2 0 1 1 1 2 1 2 8 9
Profit before tax 2 4 14 -12 9 9 22 27 35 30 70 58
Tax % 30% 20% 18% -1% 20% 16% 22% 29% 23% 25% 21% 25%
1 3 12 -12 7 8 17 19 27 22 55 43
EPS in Rs 0.18 0.50 1.81 -1.76 1.10 1.20 2.60 2.88 4.08 3.40 8.34 6.43
Dividend Payout % 22% 8% 2% -2% 9% 17% 15% 56% 49% 59% 30% 62%
Compounded Sales Growth
10 Years: 7%
5 Years: 9%
3 Years: 7%
TTM: 7%
Compounded Profit Growth
10 Years: 30%
5 Years: 21%
3 Years: 16%
TTM: 12%
Stock Price CAGR
10 Years: 31%
5 Years: 41%
3 Years: 16%
1 Year: -4%
Return on Equity
10 Years: 12%
5 Years: 17%
3 Years: 17%
Last Year: 17%

Balance Sheet

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 13 13 13 13 13 13 13 13 13 13 13 13
Reserves 82 85 97 85 91 98 109 120 146 174 227 263
39 38 8 8 4 5 7 0 6 9 9 8
19 22 25 23 28 31 35 31 30 21 29 32
Total Liabilities 154 159 143 130 136 147 164 164 195 217 278 317
52 52 22 21 22 22 26 23 24 9 94 85
CWIP 0 0 0 3 4 4 0 0 0 0 0 0
Investments 0 0 0 0 0 11 15 51 1 0 0 0
102 108 121 105 110 109 123 91 170 208 184 231
Total Assets 154 159 143 130 136 147 164 164 195 217 278 317

Cash Flows

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
4 9 -3 -2 31 11 28 7 47 35 55 47
-0 -2 41 -3 -1 -11 -2 -26 -58 -25 -45 -36
-1 -6 -34 -1 -6 -1 -7 -18 -0 -9 -12 -12
Net Cash Flow 2 1 5 -6 24 -0 19 -36 -11 2 -2 -1
Free Cash Flow 4 6 40 -5 30 12 28 6 48 35 91 47
CFO/OP 53% 83% -6% 14% 311% 150% 164% 54% 158% 189% 124% 101%

Ratios

Figures in Rs. Crores

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 119 106 100 73 45 49 25 26 32 19 18 22
Inventory Days 176 246 295 307 164 191 134 122 82 68 58 51
Days Payable 42 60 56 54 59 76 82 76 66 35 37 40
Cash Conversion Cycle 252 292 339 325 150 164 77 72 48 53 39 33
Working Capital Days 68 72 154 149 67 55 32 59 34 52 9 11
ROCE % 5% 7% 3% -10% 9% 9% 18% 20% 25% 17% 23% 23%

Insights

In beta
Mar 2023 Mar 2024 Mar 2025
Doctor Reach (Prescribers)
Count

Log in to view insights

Please log in to see hidden values.

Login
Number of Distributors (Stockists)
Count
Number of Medical Representatives (Field Force)
Count
Overall Market Ranking (IQVIA)
Rank
Therapeutic Coverage - Gynaecology
%
Therapeutic Coverage - Orthopaedics
%
Therapeutic Coverage - Dermatology
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
68.72% 68.72% 68.48% 68.09% 68.04% 67.98% 67.82% 67.77% 67.65% 67.54% 67.39% 67.89%
0.37% 0.38% 0.53% 0.73% 1.10% 2.30% 2.10% 2.10% 2.17% 2.12% 2.12% 2.44%
0.82% 0.82% 0.82% 0.84% 0.84% 0.11% 0.00% 0.00% 0.05% 0.08% 0.15% 0.22%
30.07% 30.07% 30.16% 30.33% 30.01% 29.63% 30.10% 30.11% 30.12% 30.25% 30.34% 29.44%
No. of Shareholders 13,78216,04115,78516,28215,74815,63318,47121,08522,89924,65324,89526,264

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls